EQL Pharma FY27 Q1 operating loss widens to SEK 13.7 million; gross margin drops 26 percentage points to 17%

• EQL Pharma AB posted April–June 2026 net sales of SEK 106.9 million, broadly flat from a year earlier.
• Operating result swung to an operating loss of SEK 13.7 million, while gross margin fell 26 percentage points to 17%.
• EBITDA margin turned negative at -6%; results were hit by SEK 20 million of inventory write-downs tied mainly to hospital products.
• Cash and cash equivalents rose to SEK 61.1 million, while leverage climbed to 9.8x EBITDA, above the company’s target.
• EQL launched two products, lifted its portfolio to 49, kept its 2026/27 sales growth forecast at around 15%, and still targets seven launches in 2026/27.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260806:BIT:4979:0) on August 07, 2026, and is solely responsible for the information contained therein.